Proangiogenic factors in the development of HCC in alcoholic cirrhosis

Lucey, 2011, Liver transplantation in patients with alcoholic liver disease, Liver Transpl, 17, 751, 10.1002/lt.22330 O'Shea, 2010, Alcoholic liver disease, Hepatology, 51, 307, 10.1002/hep.23258 Teli, 1995, Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver, Lancet, 346, 987, 10.1016/S0140-6736(95)91685-7 Seitz, 2006, Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress, Biol Chem, 387, 349, 10.1515/BC.2006.047 Morgan, 2004, Alcohol and hepatocellular carcinoma, Gastroenterology, 127, S87, 10.1053/j.gastro.2004.09.020 Schutte, 2012, Delayed diagnosis of HCC with chronic alcoholic liver disease, Liver Cancer, 1, 257, 10.1159/000343840 Coulon, 2011, Angiogenesis in chronic liver disease and its complications, Liver Int, 31, 146, 10.1111/j.1478-3231.2010.02369.x Lu, 2015, Hypoxia-induced secretion of platelet-derived growth factor-BB by hepatocellular carcinoma cells increases activated hepatic stellate cell proliferation, migration and expression of vascular endothelial growth factor-A, Mol Med Rep, 11, 691, 10.3892/mmr.2014.2689 Nath, 2012, Hypoxia and hypoxia inducible factors: diverse roles in liver diseases, Hepatology, 55, 622, 10.1002/hep.25497 Jaakkola, 2001, Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation, Science, 292, 468, 10.1126/science.1059796 Copple, 2009, Hypoxia-inducible factor-dependent production of profibrotic mediators by hypoxic hepatocytes, Liver Int, 29, 1010, 10.1111/j.1478-3231.2009.02015.x Moon, 2009, Reduced liver fibrosis in hypoxia-inducible factor-1alpha-deficient mice, Am J Physiol Gastrointest Liver Physiol, 296, G582, 10.1152/ajpgi.90368.2008 Fiore, 2009, Hepatocyte growth factor, vascular endothelial growth factor, glial cell-derived neurotrophic factor and nerve growth factor are differentially affected by early chronic ethanol or red wine intake, Toxicol Lett, 188, 208, 10.1016/j.toxlet.2009.04.013 Yoshiji, 2003, Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis, Gut, 52, 1347, 10.1136/gut.52.9.1347 Reiberger, 2009, Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats, J Hepatol, 51, 865, 10.1016/j.jhep.2009.06.024 Hennenberg, 2009, Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis, Br J Pharmacol, 157, 258, 10.1111/j.1476-5381.2009.00158.x Tsukamoto, 1989, Incomplete compensation of enhanced hepatic oxygen consumption in rats with alcoholic centrilobular liver necrosis, Hepatology, 9, 302, 10.1002/hep.1840090223 Kasztelan-Szczerbinska, 2014, Angiogenesis-related biomarkers in patients with alcoholic liver disease: their association with liver disease complications and outcome, Mediators Inflamm, 2014, 673032, 10.1155/2014/673032 Shariff, 2009, Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics, Expert Rev Gastroenterol Hepatol, 3, 353, 10.1586/egh.09.35 Yoshiji, 2004, Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice, Hepatology, 39, 1517, 10.1002/hep.20218 Yoshiji, 2004, Involvement of the vascular endothelial growth factor receptor-1 in murine hepatocellular carcinoma development, J Hepatol, 41, 97, 10.1016/j.jhep.2004.03.001 Park, 2000, Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis, Arch Pathol Lab Med, 124, 1061, 10.5858/2000-124-1061-IEOVEG Yamaguchi, 1998, Expression of vascular endothelial growth factor in human hepatocellular carcinoma, Hepatology, 28, 68, 10.1002/hep.510280111 Zhou, 2000, Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus, J Cancer Res Clin Oncol, 126, 57, 10.1007/s004320050009 Gershtein, 2010, Vascular endothelial growth factor and its type 2 receptor in hepatocellular carcinoma, Bull Exp Biol Med, 149, 749, 10.1007/s10517-010-1043-8 Kaseb, 2011, Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma, J Clin Oncol, 29, 3892, 10.1200/JCO.2011.36.0636 Zhan, 2013, Prognostic significance of vascular endothelial growth factor expression in hepatocellular carcinoma tissue: a meta-analysis, Hepatobiliary Surg Nutr, 2, 148 Li, 2011, Expression characteristics of hypoxia-inducible factor-1alpha and its clinical values in diagnosis and prognosis of hepatocellular carcinoma, Hepat Mon, 11, 821 Poon, 2007, High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies, Ann Surg Oncol, 14, 1835, 10.1245/s10434-007-9366-z Wada, 2006, Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alpha, Liver Int, 26, 414, 10.1111/j.1478-3231.2006.01243.x Cui, 2004, Effect of c-myc, Ki-67, MMP-2 and VEGF expression on prognosis of hepatocellular carcinoma patients undergoing tumor resection, World J Gastroenterol, 10, 1533, 10.3748/wjg.v10.i10.1533 Scartozzi, 2014, VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study, Int J Cancer, 135, 1247, 10.1002/ijc.28772 Machado, 2014, Genetic polymorphisms of proangiogenic factors seem to favor hepatocellular carcinoma development in alcoholic cirrhosis, Eur J Gastroenterol Hepatol, 26, 438, 10.1097/MEG.0000000000000044 Steffensen, 2010, The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer, Gynecol Oncol, 117, 109, 10.1016/j.ygyno.2009.11.011 Tao, 2001, Kinase insert domain receptor (KDR) extracellular immunoglobulin-like domains 4-7 contain structural features that block receptor dimerization and vascular endothelial growth factor-induced signaling, J Biol Chem, 276, 21916, 10.1074/jbc.M100763200 Glubb, 2011, Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer, Clin Cancer Res, 17, 5257, 10.1158/1078-0432.CCR-11-0379 Wang, 2007, Polymorphisms of KDR gene are associated with coronary heart disease, J Am Coll Cardiol, 50, 760, 10.1016/j.jacc.2007.04.074 Machado, 2008, Are genes really important in alcoholic liver disease?, Eur J Gastroenterol Hepatol, 20, 1244, 10.1097/MEG.0b013e328304b6dd Martins, 2005, Are genetic polymorphisms of tumour necrosis factor alpha, interleukin-10, CD14 endotoxin receptor or manganese superoxide dismutase associated with alcoholic liver disease?, Eur J Gastroenterol Hepatol, 17, 1099, 10.1097/00042737-200510000-00014 Suh, 2014, Prognostic values of vascular endothelial growth factor and matrix metalloproteinase-2 in hepatocellular carcinoma after radiotherapy, Dig Dis, 32, 725, 10.1159/000368010 Kaseb, 2009, Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature, Cancer, 115, 4895, 10.1002/cncr.24537